Hepatitis C News and Research

Latest Hepatitis C News and Research

Positive data from Nektar's NKTR-181 Phase 1 clinical study for chronic pain

Nektar Therapeutics today announced positive data from a Phase 1 clinical study of NKTR-181 evaluating multiple ascending oral doses of NKTR-181 over an 8-day treatment period in healthy subjects.

14 Dec 2011

Aethlon Hemopurifier can capture Nef protein exosomes linked with HIV

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that researchers have discovered that the Aethlon Hemopurifier is able to capture particles known as Nef protein exosomes, which contribute to the progression of human immunodeficiency virus (HIV) infection to acquired immunodeficiency syndrome.

14 Dec 2011

Drug users with HIV infection have 74% higher risk of overdose

A study from Rhode Island Hospital is the first to systematically review and analyze the literature on the association between HIV infection and overdose risk.

13 Dec 2011

Gene therapy for bleeding disorder Hemophilia B

In a landmark study, researchers used gene therapy to successfully treat six patients with severe hemophilia, a blood-clotting disorder. Despite the early nature of the study, it is promising. A single infusion using the new treatment worked in some patients for more than a year, boosting their clotting ability significantly.

12 Dec 2011

Study describes miR-124 can prevent and treat liver cancer

Cancer of the liver - rare in the United States but the third-leading cause of cancer death worldwide - can result from environmental exposures or infections like chronic hepatitis, but the link is poorly understood.

12 Dec 2011

Alios BioPharma, Vertex initiate ALS-2200 and ALS-2158 clinical study in HCV

Vertex Pharmaceuticals Incorporated and Alios BioPharma, Inc. today announced the initiation of two clinical studies for the nucleotide analogues ALS-2200 and ALS-2158, which are inhibitors of the hepatitis C NS5B polymerase.

12 Dec 2011

New guidelines for managing latent tuberculosis from CDC

The U.S. Centers for Disease Control and Prevention (CDC) has released new guidelines on treating so-called “latent” tuberculosis (TB) infection in the United States. They suggest the course of the therapy from about 9 months could be shortened to 3 months.

11 Dec 2011

Study highlights need for greater recognition of sexual and reproductive healthcare needs of teen boys

Two newly published reports by investigators at the Johns Hopkins Children's Center highlight the need for greater recognition of the sexual and reproductive healthcare needs of teen boys and enumerate the essential services this traditionally overlooked group should receive at least once a year.

9 Dec 2011

Enrollment complete in Boehringer Ingelheim's BI 201335 Phase III trial for HCV

Boehringer Ingelheim today announced that the final patient has been randomised to treatment in the large-scale Phase III clinical trial programme for BI 201335, its investigational, oral protease inhibitor for the treatment of chronic hepatitis C virus.

9 Dec 2011

Pharmacyclics, Janssen partner to develop and market PCI-32765 anti-cancer compound

Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has executed an agreement with Pharmacyclics, Inc. to jointly develop and market the anti-cancer compound, PCI-32765.

9 Dec 2011

Aethlon receives approval to begin Hemopurifier study at Sarcoma Oncology Center

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that a cancer research study to test the ex vivo effectiveness of the Aethlon Hemopurifier to capture tumor-secreted exosomes from the blood of advanced-stage cancer patients has received institutional review board approval to begin studies at the Sarcoma Oncology Center, based in Santa Monica, California.

7 Dec 2011

NanoViricides submits pre-IND Meeting Request for FluCide to FDA

NanoViricides, Inc. announced today that it has submitted a pre-IND Meeting Request to the US FDA. The Company has requested an initial meeting with the US FDA to review the Company's proposed strategy and plan for conducting safety/toxicology studies and human clinical trials required for approval of its anti-influenza clinical drug candidate, FluCide™ (i.e. NV-INF-1).

5 Dec 2011

Plasma can inactivate and prevent replication of adenoviruses

Life-threatening viruses such as HIV, SARS, hepatitis and influenza, could soon be combatted in an unusual manner as researchers have demonstrated the effectiveness of plasma for inactivating and preventing the replication of adenoviruses.

5 Dec 2011

Bristol-Myers Squibb and Tibotec partner to evaluate daclatasvir-TMC435 combination for HCV

Bristol-Myers Squibb Company announced today that it has entered into a clinical collaboration agreement with Tibotec Pharmaceuticals to evaluate the utility of daclatasvir (BMS-790052), Bristol-Myers Squibb's investigational NS5A replication complex inhibitor, in combination with Tibotec Pharmaceuticals' investigational NS3 protease inhibitor, TMC435, for the treatment of chronic hepatitis C virus (HCV).

3 Dec 2011

Baby boomers more likely to develop HCV

Experts at Montefiore Medical Center urge the general public to be tested for the Hepatitis C virus, especially baby boomers, adults born between 1946-1964, who could be most at risk for this disease. Baby boomers are more likely to have been exposed to dangerous risk factors decades ago, such as sharing a drug needle, being tattooed or pierced with unsterilized tools or receiving a tainted blood transfusion.

2 Dec 2011

Bristol-Myers Squibb, Tibotec partner for TMC435 Phase II combination study in HCV

Medivir AB, the research-based speciality pharmaceutical company focused on the development of high-value treatments for infectious diseases, announces that its development partner, Tibotec Pharmaceuticals, has entered into an agreement with Bristol-Myers Squibb Company.

2 Dec 2011

Two studies uncover limitations in screening for hepatocellular carcinoma

Two studies available in the December issue of Hepatology, a journal of the American Association for the Study of Liver Diseases, have uncovered limitations in screening for primary liver cancer, also known as hepatocellular carcinoma.

2 Dec 2011

EGCG may prevent HCV reinfection after liver transplantation

German researchers have determined that epigallocatechin-3-gallate (EGCG)—a flavonoid found in green tea—inhibits the hepatitis C virus (HCV) from entering liver cells.

1 Dec 2011

Immune system stimulant used as suppressor to treat chronic graft-versus-host disease

In a study that seems to pivot on a paradox, scientists at Dana-Farber Cancer Institute have used an immune system stimulant as an immune system suppressor to treat a common, often debilitating side effect of donor stem cell transplantation in cancer patients. The effect, in some cases, was profound.

1 Dec 2011

With HIV and unaware of it: CDC report

Over the years diagnosis with HIV/AIDS has ceased to become a death sentence. However a new Centers for Disease Prevention and Control (CDC) report says only one in four Americans with AIDS has the virus under control with adequate medication. Figures also show that about 16,000 people die from the disease annually, and the number of new infections each year in the U.S. has held steady at about 50,000 in recent years.

30 Nov 2011

Hepatitis C News and Research

Latest Hepatitis C News and Research

Positive data from Nektar's NKTR-181 Phase 1 clinical study for chronic pain

Aethlon Hemopurifier can capture Nef protein exosomes linked with HIV

Drug users with HIV infection have 74% higher risk of overdose

Gene therapy for bleeding disorder Hemophilia B

Study describes miR-124 can prevent and treat liver cancer

Alios BioPharma, Vertex initiate ALS-2200 and ALS-2158 clinical study in HCV

New guidelines for managing latent tuberculosis from CDC

Study highlights need for greater recognition of sexual and reproductive healthcare needs of teen boys

Enrollment complete in Boehringer Ingelheim's BI 201335 Phase III trial for HCV

Pharmacyclics, Janssen partner to develop and market PCI-32765 anti-cancer compound

Aethlon receives approval to begin Hemopurifier study at Sarcoma Oncology Center

NanoViricides submits pre-IND Meeting Request for FluCide to FDA

Plasma can inactivate and prevent replication of adenoviruses

Bristol-Myers Squibb and Tibotec partner to evaluate daclatasvir-TMC435 combination for HCV

Baby boomers more likely to develop HCV

Bristol-Myers Squibb, Tibotec partner for TMC435 Phase II combination study in HCV

Two studies uncover limitations in screening for hepatocellular carcinoma

EGCG may prevent HCV reinfection after liver transplantation

Immune system stimulant used as suppressor to treat chronic graft-versus-host disease

With HIV and unaware of it: CDC report

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Hepatitis C News and Research

Latest Hepatitis C News and Research

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Newsletters you may be interested in